GT Biopharma Inc. saw a price increase of 8.73% as it crossed above the 5-day SMA, despite the Nasdaq-100 and S&P 500 experiencing declines of 0.44% and 0.30%, respectively.
The surge is attributed to GT Biopharma advancing its GTB-3650 clinical trial to Cohort 4, where patients are receiving a dosing of 10μg/kg/day. This advancement indicates potential efficacy in treating resistant blood cancers and enhances the company's investment outlook, especially with the oncology market projected to grow significantly in the coming years. Additionally, the safety profile of GTB-3650 has been confirmed with no dose-limiting toxicities observed in earlier cohorts, further boosting confidence in the trial's success.
This positive development not only reflects the company's commitment to innovation in tumor immunotherapy but also positions GT Biopharma favorably within a rapidly expanding market. Investors are likely to keep a close eye on the upcoming trial updates expected in Q1 2026.
Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast GTBP stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GTBP is 8.00 USD with a low forecast of 8.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.680
Low
8.00
Averages
8.00
High
8.00
Current: 0.680
Low
8.00
Averages
8.00
High
8.00
Roth Capital
Buy
downgrade
$11 -> $8
2025-11-17
Reason
Roth Capital
Price Target
$11 -> $8
AI Analysis
2025-11-17
downgrade
Buy
Reason
Roth Capital lowered the firm's price target on GT Biopharma to $8 from $11 and keeps a Buy rating on the shares. GT Biopharma closed Q3 with $2.6M in cash, sufficient to fund operations into 1Q26, the analyst tells investors in a research note. The company is advancing a Phase 1 trial of second-generation TriKE GTB-3650 in relapsed/refractory CD33+ hematologic malignancies, with initial data expected in 1Q26, and has resumed preclinical development of GTB-5550 for B7H3+ solid tumors, targeting an IND submission by YE25/1Q26.
About GTBP
GT Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of immuno-oncology therapeutic products based on its proprietary Tri-specific Killer Engager (TriKE) natural killer (NK) cell engager platform. Its TriKE platform is designed to harness and enhance the cancer-killing abilities of a patient’s immune system’s natural killer cells. Its product candidate pipeline includes GTB-3550, GTB-3650, GTB-5550, GTB-7550, GTB-6550, GTB-1050, and other product candidates. GTB-3550 is a TriKE comprised of two single-chain variable fragments (scFv) composed of the variable regions of the heavy and light chains of anti-CD16 and anti-CD33 antibodies and a modified form of IL-15. GTB-3650 is a TriKE which targets CD33 on the surface of myeloid leukemias. The Company also has a worldwide license agreement with the University of Minnesota to further develop and commercialize therapies using TriKE technology.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
